Latest News

What Trauma Taught Me That Medical School Never Did

What Trauma Taught Me That Medical School Never Did

Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body. Like many physicians, I was trained to think of trauma primarily as a psychological injury,...

read more

Latest News

CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

The CagriSema FDA review has become one of the most closely watched regulatory processes in metabolic medicine. Novo Nordisk filed a New Drug Application for its once-weekly obesity combination in December 2025, and a decision is widely expected in the final quarter...

read more
The Evidence Gap in Precision Prevention

The Evidence Gap in Precision Prevention

Preventive medicine is entering a new era. Advances in genomics, biomarker testing, continuous monitoring technologies, imaging, and data analytics are enabling clinicians to identify disease risk with a level of precision that would have been unimaginable just a...

read more
Are Animal Models Limiting Progress in Product Development?

Are Animal Models Limiting Progress in Product Development?

While animal models have played a central role in safety assessment and biological research for decades, advances in cellular biology, computational modelling, and micro physiological systems are prompting scientists to explore new ways of generating human-relevant...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

The Microbiome: The Missing Layer in Modern Metabolic Care

The Microbiome: The Missing Layer in Modern Metabolic Care

Over the last decade, obesity management has undergone a structural transformation. What was once a field dominated almost exclusively by bariatric surgery has evolved into a far more nuanced metabolic discipline. The rise of GLP-1 receptor agonists and dual incretin...

read more
FDA Overhauls Pharmacokinetic Study Requirements

FDA Overhauls Pharmacokinetic Study Requirements

FDA Overhauls Pharmacokinetic Study Requirements in New Biosimilar Draft Guidance The US Food and Drug Administration (FDA) has overhauled biosimilar pharmacokinetic study requirements in new draft guidance issued on 9 March 2026, aimed at further reducing the time...

read more
Breakthroughs in the Lab – Blind Spots in Reality 

Breakthroughs in the Lab – Blind Spots in Reality 

Obesity care is at a turning point. GLP-1s like Ozempic and Mounjaro have upended weight loss culture – and the research backs them up. For the first time, multiple randomized trials have found that anti-obesity medications can lead to an average 15-20% weight loss....

read more
The Microbiome: The Missing Layer in Modern Metabolic Care

The Microbiome: The Missing Layer in Modern Metabolic Care

Over the last decade, obesity management has undergone a structural transformation. What was once a field dominated almost exclusively by bariatric surgery has evolved into a far more nuanced metabolic discipline. The rise of GLP-1 receptor agonists and dual incretin...

read more
FDA Overhauls Pharmacokinetic Study Requirements

FDA Overhauls Pharmacokinetic Study Requirements

FDA Overhauls Pharmacokinetic Study Requirements in New Biosimilar Draft Guidance The US Food and Drug Administration (FDA) has overhauled biosimilar pharmacokinetic study requirements in new draft guidance issued on 9 March 2026, aimed at further reducing the time...

read more
Breakthroughs in the Lab – Blind Spots in Reality 

Breakthroughs in the Lab – Blind Spots in Reality 

Obesity care is at a turning point. GLP-1s like Ozempic and Mounjaro have upended weight loss culture – and the research backs them up. For the first time, multiple randomized trials have found that anti-obesity medications can lead to an average 15-20% weight loss....

read more

Featured Articles

FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 31 July 2026. Covering target action dates from August to December 2026. The closing stretch of the third quarter has become the busiest regulatory window of 2026. Between early August and the end of September, the US Food and Drug Administration faces...
Pipette dispensing into lab vials with glowing DNA helix and genetic sequence data for Life Science Daily News

Life Science Daily News: Eight Months of Growth and a Global Community Taking Shape

Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare professionals, communications specialists and industry professionals should be able to publish their own work directly to a specialist audience,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Why a New Era of Medical Innovation is Taking Shape

Why a New Era of Medical Innovation is Taking Shape

Over the next decade, modern medicine is poised to undergo a redefinition that has not been seen in generations. The surge in innovation, transformational scientific discoveries and rapidly maturing technologies is redefining patient outcomes. The biotech industry is...

read more
Summary: England Rare Diseases Action Plan 2026

Summary: England Rare Diseases Action Plan 2026

The England Rare Diseases Action Plan 2026 outlines how the Department of Health and Social Care and partner organisations are delivering commitments under the UK Rare Diseases Framework to improve outcomes for people living with rare conditions in England. The report...

read more
ESGO 2026: Elenagen Phase II Data in Platinum-Resistant OC

ESGO 2026: Elenagen Phase II Data in Platinum-Resistant OC

At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for...

read more
Global Funding Shifts Redraw Life Sciences Innovation Map

Global Funding Shifts Redraw Life Sciences Innovation Map

The life sciences sector is experiencing a fundamental reshaping of its innovation geography as funding pressures, policy shifts, and geopolitical tensions redraw the competitive landscape across continents. While research funding constraints in the United States...

read more

Further News

Complement Inhibitor Setback: Sanofi Halts CIDP Study

Sanofi has halted a late-stage trial of its experimental complement inhibitor riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), a setback that analysts say could create volatility across the wider complement inhibitor field. The company said in...

Clinical Trials Roundup | 12 June 2026

Survodutide delivers dual Phase 3 success in obesity and metabolic liver disease at ADA 2026, secukinumab becomes the first targeted biologic to demonstrate sustained remission in polymyalgia rheumatica, dapirolizumab pegol meets its Phase 3 primary endpoint in...

Foundayo vs Rybelsus: The Oral GLP-1 Guide for 2026

The oral GLP-1 market has changed faster in the past six months than in the previous six years. Where once Rybelsus stood alone as the only GLP-1 pill available, patients and clinicians must now navigate three distinct oral products, each with a different molecule, a...

The Case for Agility: Why Biopharma Must Embrace Adaptive Trial Designs

For decades, the landscape of clinical research was dominated by fixed, traditional trial designs. In these legacy studies, the primary objective was often maintaining a strict, unchanging protocol from inception to conclusion. But the landscape of modern medicine has...

GSK’s $10.6 Billion Nuvalent Deal: Reshaping the Lung Cancer Drug Race

Two FDA decision dates, 18 September and 27 November, are now the most important dates on GSK's calendar. On 9 June 2026, the British pharmaceutical giant announced it had agreed to acquire Cambridge, Massachusetts-based Nuvalent for $10.6 billion in cash, securing...

FDA Drug Approval Decisions: June and July 2026

The summer months at the United States Food and Drug Administration are typically among the busiest on the regulatory calendar, and 2026 is proving no exception. With a succession of high-profile FDA drug approval decisions concentrated in June and July 2026, the...

Importance of Targeted Radiotherapeutics in Treating CNS Cancers

Radiation therapy is one of the important tools in the fight against cancer. About 50% of all cancer patients receive radiation therapy. Few modalities have had the same lasting impact across such a broad range of tumor types. In central nervous system (CNS) oncology,...

How Compassion Protects Healthcare Workers from Empathy Fatigue

Working professionals know the feeling of being worn out at the end of a long, demanding day; however, burnout is considered a more intense, full-body breakdown resulting from longer-term exhaustion. Herbert Freudenberger, Ph.D., who coined the term burnout, defined...

Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO

When Brian Wolpin, Professor of Medicine at Harvard Medical School and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, advanced to the next slide during the plenary session at the 2026 ASCO (American Society of...

Clinical Insight: The Future of Sensory-Based Therapeutics in Healthcare

The role of sensory systems in human health has long been established within biological and neuroscientific research. Olfactory, auditory, and tactile pathways are deeply integrated into the body’s regulatory networks, influencing emotional processing, cognitive...

Dementia Relief Through Silence and Brain Wave Modulation

In silence, the brain regenerates, growing new neurons in the hippocampus which is the cerebral center of memory, spatial navigation and emotional regulation (Kriste, Nicola, Kronenberg, Walker, Liu, & Kempermann, 2015). Silence has also been shown to be relaxing...

The Silent Epidemic: Workplace Bullying in Healthcare

Workplace Bullying in Healthcare and the Leadership Response Healthcare is one of the most demanding professional environments on earth. Clinicians make high-stakes decisions under pressure, routinely absorb the grief and trauma of others, and operate within systems...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.